Through a joint project and on common ground, a large number of investigators from US trial groups and the National Cancer Institute reached consensus on issues regarding the strength of pre-clinical data and study designs via extensive interactions
“The Children’s Oncology Group is excited about the activation of its ComboMATCH treatment trial, EAY191-C1, which will be open to patients with tumors harboring activating MAPK pathway mutations. Our prior experience with the NCI-COG Pediatric MATCH trial2 showed that MAPK pathway mutations are the most common targetable alterations in children with relapsed or refractory solid tumors,” said Douglas S. Hawkins, MD, group chair of the Children’s Oncology Group.
"Through ComboMATCH, the NCTN groups and NCI are taking advantage of translational ideas, pre-clinical investigations, and early clinical experience from a large number of investigators working closely together," said James M. Ford, MD, co-leader of ComboMATCH and leader of the coordination effort by the ECOG-ACRIN Cancer Research Group.
“NRG Oncology recently activated its first two ComboMATCH precision medicine initiative trials and we are engaged in accruing patients to this incredibly important effort. EAY191-N2 will be assessing two drugs for patients with hormone-receptor positive metastatic breast cancer with NF1 mutation and EAY191-N4 will be testing two drugs for recurrent or persistent ovarian and endometrial cancers with a RAS pathway mutation,” said Roisin O’Cearbhaill, MD, the NRG Oncology scientific representative. “We also are eager to open three more ComboMATCH trials later this year.”
“The SWOG Cancer Research Network has launched the first of its ComboMATCH treatment trials, EAY191-S3, to test whether adding targeted therapy with ipatasertib to standard chemotherapy improves outcomes for patients whose solid tumors have a mutation in an AKT gene. The study enrolls patients with advanced or metastatic non-breast tumors,” said Charles D. Blanke, MD, group chair of the SWOG Cancer Research Network. “SWOG also looks forward to testing other targeted therapy combinations within the NCI’s ComboMATCH platform in the coming months and years.”
View this press release on EurekAlert
Read the National Cancer Institute companion press release:
NCI’s ComboMATCH initiative will test new drug combinations guided by tumor biology